News - Stealth BioTherapeutics Inc.

Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference

BOSTON, April 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8th, at ...

Apr 2, 2019

Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD

BOSTON, March 28, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has dosed the first patient in ReCLAIM-2, a Phase 2 study of elamipretide in patients with dry age-related macular ...

Mar 28, 2019

Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option

BOSTON, March 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has issued an additional 588,232 American Depositary Shares ("ADSs") at the public offering price of $12.00 per ADS, resulting ...

Mar 4, 2019